Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 5/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Echinomycin SCHEMBL29420869 | 1.00 | RIPK1 (0.32) | RIPK1 | |
| Echinomycin SCHEMBL29529894 | 1.00 | RIPK1 (0.32) | RIPK1 | |
| Echinomycin SCHEMBL13464701 | 1.00 | RIPK1 (0.32) | RIPK1 | |
| Echinomycin SCHEMBL63091 | 1.00 | RIPK1 (0.32) | RIPK1 | |
| Echinomycin SCHEMBL30725384 | 1.00 | RIPK1 (0.32) | RIPK1 | |
| Echinomycin SCHEMBL18506201 | 1.00 | RIPK1 (0.32) | RIPK1 | |
| Echinomycin SCHEMBL13928604 | 1.00 | RIPK1 (0.32) | RIPK1 | |
| SCHEMBL20323949 | 0.96 | RIPK1 (0.31) | RIPK1 | |
| SCHEMBL12556535 | 0.95 | RIPK1 (0.31) | RIPK1 | |
| SCHEMBL29378829 | 0.95 | RIPK1 (0.32) | RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119858-A1 | T5 EXONUCLEASE-BASED METHOD TO IDENTIFY DNA TOPOISOMERASE INHIBITORS | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2022-04-21 | — | — | US | disclosed |
| US-11268129-B1 | T5 exonuclease-based method to identify DNA topoisomerase inhibitors | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2022-03-08 | — | — | US | disclosed |
| US-20170035832-A1 | USES OF HYPOXIA-INDUCIBLE FACTOR INHIBITORS | OncoC4, Inc. | 2017-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170035832-A1 | USES OF HYPOXIA-INDUCIBLE FACTOR INHIBITORS | HIF1AN, HIF1A, EGLN2 | RIPK1 3174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.